The Fallacy of CoTCCC "Approved" vs. "Recommended"

Trigger Warning: This blog article is based on the author's personal experience as a trained physician, US military veteran, EMT/Paramedic who, since 2012, has been working in and teaching tactical and operational medicine primarily in the SWHEM, working with many resource-limited teams, units, and corps. There are many in the world who have never heard of, care about, nor are subject to DoD or CoTCCC guidelines or opinions and make equipment decisions based on cost and local availability.

What is CoTCCC?

The Committee on Tactical Combat Casualty Care (CoTCCC) is a group of medical professionals, including trauma surgeons, emergency medicine physicians, combat medics, and other experts, dedicated to improving trauma care in combat and tactical environments. Established in the 1990s to address preventable deaths in military settings, CoTCCC reviews scientific literature, analyzes data, and develops evidence-based recommendations for medical devices and techniques, such as tourniquets. Their work has made them a respected authority in tactical medicine, particularly within military and law enforcement communities.

However, CoTCCC is not a regulatory body. Unlike the U.S. Food and Drug Administration (FDA), which has legal authority to approve medical devices for use in the USA, CoTCCC lacks the power to enforce regulations or legally approve or disapprove products. Instead, it serves solely as an advisory group, providing guidance based on its research and expertise, primarily for military and tactical contexts.

Investigating the Claims

The claims that "CoTCCC-approved" tourniquets are "better" or "legal to use" in the USA compared to other tourniquets stem from misunderstandings about CoTCCC's role and the meaning of their recommendations. Let’s break these claims down:

Are "CoTCCC-Approved" Tourniquets "Better"?

CoTCCC considers tourniquets in light of tactical combat scenarios, prioritizing factors like rapid deployment, one-handed application, and durability in extreme conditions. It is important to be precise about where the evidence behind the list actually comes from. The original 2005 recommendation (CAT, SOFTT, EMT) rested on controlled human-volunteer testing of seven commercial tourniquets performed by the U.S. Army Institute of Surgical Research (Walters et al., Prehosp Emerg Care 2005;9:416-22) and was later reinforced by battlefield outcome data (Kragh et al., Ann Surg 2009;249:1-7). CoTCCC adopted those results; it did not generate them. The committee has no laboratory and has never run a standardized tourniquet test protocol of its own.

The 2019 update was different in kind. It was a review of existing literature and existing test data, much of it manufacturer-generated, followed by a committee vote. The authors of that review (Montgomery et al., J Spec Oper Med 2019;19(4)) state in their own abstract that the paper "highlights the lack of unbiased data, official reporting mechanisms, and official studies with established criteria for evaluating tourniquets. Upon review of the data, the CoTCCC voted to update the recommendations in April 2019." That is an expert-panel consensus vote, not a trial, not dedicated testing, and not a meta-analysis. The devices on the list are well regarded for military and tactical use, and that reputation is earned, but the mechanism behind the list is narrower than most people assume.

However, this does not mean they are universally superior:

• Context Matters: CoTCCC’s focus is on tactical environments. In civilian settings (e.g., urban EMS or hospitals), other tourniquets might perform equally well or better, depending on the situation. For instance, a tourniquet optimized for prolonged use or ease of training might be more suitable for civilian first responders.
• Not All Tourniquets Are Reviewed: CoTCCC does not evaluate every tourniquet on the market. Newer, foreign, or less well-known models might be just as effective but absent from their recommended list simply because they haven’t been assessed. (Think SnakeStaff, Spain's TIE, and the Ukrainian DNIPRO & SICH tourniquets)
• Evolving Recommendations: CoTCCC’s list has changed over time. Until 2019, only a few tourniquets were recommended, but that year, they expanded their list based on new evidence. This shows that "better" is a moving target, and non-recommended tourniquets aren’t necessarily inferior—they may just lack CoTCCC’s review.

Thus, while CoTCCC-recommended tourniquets are highly regarded for tactical use, they are not inherently "better" than all other tourniquets, especially outside military contexts.

Are "CoTCCC-Approved" Tourniquets the Only Legal Option?

In the USA, the legal marketing of tourniquets is governed by the FDA, not by CoTCCC recommendations. Here the common language gets it wrong in the other direction: there is no such thing as an "FDA-approved" limb tourniquet either. A nonpneumatic tourniquet is a Class I device under 21 CFR 878.5900 (product code GAX) and is exempt from 510(k) premarket notification. The FDA does not review these devices before they go to market. The manufacturer registers its establishment and lists the device, and must follow general controls and quality-system requirements. The correct term is FDA-registered or FDA-listed. Any tourniquet that is lawfully listed can be legally marketed and used, regardless of CoTCCC’s stance.

• FDA vs. CoTCCC: An FDA-listed tourniquet that isn’t recommended by CoTCCC is still legal for use by civilians, EMS, or hospitals. Conversely, a CoTCCC-recommended tourniquet must still be FDA-listed to be legally sold in the USA. If the federal regulator does not gate the device before market, a DoD advisory committee certainly does not.
• No Legal Mandate: There is no federal or state law or regulation requiring tourniquets to be "CoTCCC-approved" for legal use. Individual military services and units may write purchasing specifications that call for CoTCCC-recommended devices; that is a buyer’s procurement requirement inside DoD, not a law, and it has no reach into civilian EMS, law enforcement, schools, or industry. State EMS protocols and agency SOPs that reference the list are local policy decisions, revocable by the same body. CoTCCC’s recommendations are influential but not legally binding.
• Liability: The standard of care in a negligence claim is what a reasonable, similarly trained provider would do, established through expert testimony, not by a DoD committee list. A provider who applies a non-listed but FDA-listed tourniquet correctly, per training, is not negligent by virtue of the brand. A CoTCCC-recommended device applied across a joint or too loosely is still a deviation. The list does not indemnify anyone. (This is a description of how the doctrine is structured, not legal advice.)

The claim that "CoTCCC-approved" tourniquets are the only legal option is false. Legality hinges on FDA registration and listing, not CoTCCC’s advisory guidance.

The Fallacy of "Approved" vs. "Recommended"

A key misunderstanding fueling these claims is the conflation of "approved" and "recommended." This fallacy has significant implications:

• "Approved" Implies Regulation: In a regulatory context (e.g., FDA premarket approval of a high-risk Class III device), "approved" means a device has met legal standards for safety and efficacy, granting it official authorization for use. Limb tourniquets never go through that process, and CoTCCC does not have this authority.
• "Recommended" Reflects Expertise: When CoTCCC "recommends" a tourniquet, it means they’ve reviewed evidence and found it effective for tactical combat care. This is an expert opinion, not a legal endorsement.

The term "CoTCCC-approved" is often misused in marketing or casual discussion, suggesting a level of authority CoTCCC doesn’t possess. This fallacy arises because:

• Respect Breeds Confusion: CoTCCC’s expertise in tactical medicine lends their recommendations significant credibility, leading some to assume they carry regulatory weight.
• Miscommunication: Phrases like "CoTCCC-approved" sound definitive, obscuring the advisory nature of their role.

In reality, CoTCCC only recommends tourniquets, and equating this with "approval" overstates their influence and misrepresents the legal landscape.

CoTCCC’s Advisory Role and Limitations

As an advisory group, CoTCCC’s mission is to guide best practices in tactical combat casualty care, not to regulate or comprehensively evaluate all medical devices. This role comes with inherent limitations:

No Regulatory Authority

Unlike the FDA, CoTCCC cannot enforce its recommendations or dictate which tourniquets can be used. Their guidance is voluntary, aimed at informing military units, medics, and other tactical personnel. Regulatory decisions remain the FDA’s domain.

No Mechanism for Submitting New Products

CoTCCC does not offer a formal process for manufacturers to submit new tourniquets for evaluation. There is no published application, fee, test protocol, pass/fail standard, or review timeline. The committee’s own 2019 review paper identifies the absence of "official reporting mechanisms" and of "official studies with established criteria for evaluating tourniquets." Unlike regulatory bodies with clear submission pathways, CoTCCC relies on its own initiative to review products, often based on existing data or devices already in use. This means:

• Innovative or niche tourniquets may go unreviewed, not because they’re ineffective, but because they haven’t caught CoTCCC’s attention.
• Manufacturers have no direct way to seek CoTCCC’s endorsement, limiting the scope of their recommendations.

No Set Schedule for Updates

CoTCCC does not follow a fixed timeline for reviewing or updating its recommendations. Updates occur sporadically, driven by new evidence or committee priorities rather than a structured plan. For example:

• The 2019 expansion of their tourniquet list came after years of relying on a smaller set of recommendations, reflecting a reactive rather than proactive approach.
• There are no publicized plans for when or how future equipment will be evaluated, leaving uncertainty about when new tourniquets might be considered.

These limitations mean CoTCCC’s recommendations are a snapshot of evaluated devices at a given time, not a comprehensive or forward-looking assessment of all tourniquets.

The Improving Police CARE Act Just Made the Problem Worse

Until recently, the "approved vs. recommended" confusion was a marketing and training problem. In December 2025 it became a procurement problem written into federal law.

The Improving Police CARE Act (Critical Aid for Responding to Emergencies; S. 1595 / H.R. 5864, Cornyn–Whitehouse, Gonzales–Panetta) was signed into law on December 31, 2025 as part of the FY2026 National Defense Authorization Act. It amends Section 521 of the Omnibus Crime Control and Safe Streets Act (34 U.S.C. 10202), the statute behind the Edward Byrne Memorial Justice Assistance Grant (Byrne-JAG) program. The intent is good: get trauma kits into police vehicles and fund the training to use them. The law directs the Director of the Bureau of Justice Assistance to publish trauma-kit performance standards within 180 days, and it lists the required contents of a grant-eligible kit. The first item on that list, in the bill text, is "a tourniquet recommended by the Committee on Tactical Combat Casualty Care."

Read that against everything above. Congress has now tied federal grant eligibility to the recommendation list of an advisory committee that, by its own published account, has no established evaluation criteria, no official reporting mechanism, no submission pathway for manufacturers, no lab, and no update schedule. The limb-tourniquet list was last revised by the April 2019 vote. As of this writing it still reflects that vote. In practical terms, a public safety agency spending Byrne-JAG money on trauma kits can only buy tourniquet models that a committee voted on in 2019. No newer model, variant, generation, or technology qualifies until CoTCCC convenes and votes again, and there is no mechanism by which a manufacturer, an agency, or a trauma surgeon can request that it do so.

The drafters almost certainly reached for "CoTCCC-recommended" because it sounded like a quality standard. It is not one. It is a snapshot. Writing a snapshot into a statute converts it into a freeze. Several things follow:

• Scope: The restriction applies only to trauma kits bought with Byrne-JAG funds under the CARE Act provisions. An agency can still buy any FDA-listed tourniquet with its own budget, with other grant money, or through other programs. Nothing in the law bans a device; it limits what this one funding stream will pay for.
• Effect on the market: Whatever the intent, the practical effect is a federally funded, closed market for the handful of manufacturers whose devices were on the 2019 list, with no door for anyone else to walk through. Good technology that has entered the field since 2019 is locked out of this funding regardless of its performance. Agencies that would benefit from it will not have access to it under these funds.
• Legal exposure: Expect the "stifles competition" argument to be raised, but do not expect it to win in court. Congress has broad authority to attach conditions to federal grants, and antitrust law does not reach a statute. The realistic pressure points are the BJA standards themselves, which must be developed in consultation with trauma surgeons, EMS professionals, and law enforcement and are the only place where the practical meaning of "recommended" can be interpreted; a technical amendment; or CoTCCC updating its list. Agencies and manufacturers who care about this should be engaging BJA during the standards window, not planning lawsuits.
• Buyer beware: If your agency is counting on Byrne-JAG money for trauma kits, confirm the tourniquet in the kit is on the current CoTCCC list before you order, and make sure the vendor's "CoTCCC-recommended" claim refers to the exact model and generation, not the brand family.
• Status as of October 1, 2026: The statute gave BJA 180 days (to roughly June 29, 2026) to publish the trauma-kit performance standards. We have not located them, and the FY2026 JAG State and Local Formula solicitations released August 25, 2026 do not mention trauma kits, tourniquets, or Section 521(d) at all. Because 521(d)(2) conditions grant-funded kit purchases on those standards, agencies are currently operating in a gap the statute did not anticipate.

This will be revisited once the first agency is told its preferred tourniquet is ineligible and asks why. Until then, the CARE Act is the clearest example yet of what happens when "recommended" gets mistaken for "approved."

Conclusion

The claims that "CoTCCC-approved" tourniquets are inherently better or legally required in the USA compared to other tourniquets are rooted in misconceptions about CoTCCC’s role:

• Effectiveness: CoTCCC-recommended tourniquets carry a credible expert-consensus signal, and the original three rest on real USAISR testing and battlefield outcome data, but they aren’t universally "better." The 2019 expansion was a data review and committee vote, not dedicated testing. Other FDA-listed tourniquets may be equally effective, especially in non-tactical settings, and CoTCCC’s limited review process excludes some potentially excellent options.
• Legality: Legal marketing in the USA depends on FDA registration and listing (Class I, 21 CFR 878.5900, 510(k)-exempt), not CoTCCC recommendations. Any lawfully listed tourniquet is legal, debunking the idea that CoTCCC’s list defines legality.
• "Approved" vs. "Recommended": The fallacy of calling CoTCCC’s recommendations "approvals" exaggerates their authority. They advise, not regulate.
• Advisory Limitations: As a non-regulatory body, CoTCCC lacks mechanisms for new product submissions, set evaluation schedules, or plans for future reviews, restricting their recommendations to a subset of available tourniquets.
• Statutory Freeze: The Improving Police CARE Act (2025) now ties Byrne-JAG trauma-kit funding to that 2019 snapshot, locking federally funded agencies out of anything newer until the committee votes again.

When choosing a tourniquet, users should confirm FDA registration and listing for legality and consult multiple sources—including CoTCCC—for effectiveness, rather than assuming CoTCCC’s recommendations are the final word.

Sources

• Montgomery HR, Hammesfahr R, Fisher AD, Cain JS, Greydanus DJ, Butler FK, Goolsby C, Eastman AL. 2019 Recommended Limb Tourniquets in Tactical Combat Casualty Care. J Spec Oper Med. 2019;19(4). PMID 31910470.
• U.S. FDA Product Classification: Tourniquet, nonpneumatic. 21 CFR 878.5900, Class I, product code GAX, 510(k)-exempt.
• Walters TJ, Wenke JC, Kauvar DS, McManus JG, Holcomb JB, Baer DG. Effectiveness of self-applied tourniquets in human volunteers. Prehosp Emerg Care. 2005;9(4):416-422.
• Kragh JF Jr, Walters TJ, Baer DG, et al. Survival with emergency tourniquet use to stop bleeding in major limb trauma. Ann Surg. 2009;249(1):1-7.
• Shackelford SA, Butler FK, Kragh JF Jr, et al. Optimizing the Use of Limb Tourniquets in Tactical Combat Casualty Care: TCCC Guidelines Change 14-02. J Spec Oper Med. 2015;15(1):17-31.
• Improving Police CARE Act, S. 1595 / H.R. 5864, 119th Congress; enacted December 31, 2025 as part of the FY2026 National Defense Authorization Act, amending 34 U.S.C. 10202. Bill text: govinfo.gov (BILLS-119s1595is).